| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | 144 |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | FORM S-8 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – |
| 23 Sep 2026 | 144 |
| 17 Sep 2026 |
Form 4: Denner Alexander J, Director
Received 3,694 shares as a grant or award |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to ... |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 22 Jul 2026 |
Form 4: Silber Jeffrey, SVP, CMO, Head-Res&Drug
Received 137,036 shares as a grant or award |
| 22 Jul 2026 |
Form 3: Silber Jeffrey, SVP, CMO, Head-Res&Drug
No securities owned |
| 09 Jul 2026 |
Form 4: Silver Ronald, PFO & PAO
Sold 127,890 shares ($578K) |
| 07 Jul 2026 | 144 |
| 18 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No. 1 (this “Amendment”) is made to the Amended and Restated 2019 Equity Incentive Plan (the “Plan”) of Ironwood Pharmaceuticals, Inc. (the “Company”). |
Loading...